The association of statin therapy and high-sensitivity C‐reactive protein level for predicting clinical outcome in acute non-cardioembolic ischemic stroke

Clinica Chimica Acta

Volumn 413, Issue 23-24, 2012, Pages 1861-1865

  Tsai, Nai Wen ^a   Lee, Lian Hui ^a   Huang, Chi Ren ^a   Chang, Wen Neng ^a   Chen, Shang Der ^a   Wang, Hung Chen ^a   Lin, Yu Jun ^a,b   Lin, Wei Che ^a   Chiang, Yi Fang ^a   Lin, Tsu Kung ^a   Cheng, Ben Chung ^a,b   Su, Yu Jih ^a   Kung, Chia Te ^a   Hung, Shu Hua ^c   Chang, Hsueh Wen ^b   Lu, Cheng Hsien ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Clinical outcome; High sensitivity C reactive protein; Ischemic stroke; Statin

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; BRAIN ISCHEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; ADOLESCENT; AGED; BLOOD; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; METABOLISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROGNOSIS; STROKE; YOUNG ADULT;

EID: 84865087485     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.07.021     Document Type: Article

References (32)

1. Danton, G.H., Dietrich, W.D., Inflammatory mechanisms after ischemia and stroke. J Neuropathol Exp Neurol 62 (2003), 127–136.
2. Samson, Y., Lapergue, B., Hosseini, H., Inflammation and ischaemic stroke: current status and future perspectives. Rev Neurol (Paris) 161 (2005), 1177–1182.
3. Huang, J., Upadhyay, U.M., Tamargo, R.J., Inflammation in stroke and focal cerebral ischemia. Surg Neurol 66 (2006), 232–245.
4. Tsai, N.W., Chang, W.N., Shaw, C.F., et al. The value of leukocyte adhesion molecules in patients after ischemic stroke. J Neurol 256 (2009), 1296–1302.
5. Vila, N., Castillo, J., Davalos, A., Esteve, A., Planas, A.M., Chamorro, A., Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke 34 (2003), 671–675.
6. Frijns, C.J., Kappelle, L.J., Inflammatory cell adhesion molecules in ischemic cerebrovascular disease. Stroke 33 (2002), 2115–2122.
7. Everett, B.M., Kurth, T., Buring, J.E., Ridker, P.M., The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women. J Am Coll Cardiol 48 (2006), 2235–2242.
8. Makita, S., Nakamura, M., Satoh, K., et al. Serum C-reactive protein levels can be used to predict future ischemic stroke and mortality in Japanese men from the general population. Atherosclerosis 204 (2009), 234–238.
9. Alberts, A.W., Discovery, biochemistry and biology of lovastatin. Am J Cardiol 62 (1988), 10J–15J.
10. Lefer, D.J., Statins as potent antiinflammatory drugs. Circulation 106 (2002), 2041–2042.
11. Kwak, B.R., Mach, F., Statins inhibit leukocyte recruitment: new evidence for their anti-inflammatory properties. Arterioscler Thromb Vasc Biol 21 (2001), 1256–1258.
12. Moonis, M., Kane, K., Schwiderski, U., Sandage, B.W., Fisher, M., HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke 36 (2005), 1298–1300.
13. Amarenco, P., Goldstein, L.B., Szarek, M., et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 38 (2007), 3198–3204.
14. Marti-Fabregas, J., Gomis, M., Arboix, A., et al. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 35 (2004), 1117–1121.
15. Greisenegger, S., Mullner, M., Tentschert, S., Lang, W., Lalouschek, W., Effect of pretreatment with statins on the severity of acute ischemic cerebrovascular events. J Neurol Sci 221 (2004), 5–10.
16. Ridker, P.M., Danielson, E., Fonseca, F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008), 2195–2207.
17. Tsai, N.W., Lin, T.K., Chang, W.N., et al. Statin pre-treatment is associated with lower platelet activity and favorable outcome in patients with acute non-cardio-embolic ischemic stroke. Crit Care, 15, 2011, R163.
18. Adams, H.P. Jr., Bendixen, B.H., Kappelle, L.J., et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24 (1993), 35–41.
19. Goldstein, L.B., Adams, R., Alberts, M.J., et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 37 (2006), 1583–1633.
20. Sacco, R.L., Adams, R., Albers, G., et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 37 (2006), 577–617.
21. Sulter, G., Steen, C., De Keyser, J., Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke 30 (1999), 1538–1541.
22. Ridker, P.M., Rifai, N., Rose, L., Buring, J.E., Cook, N.R., Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002), 1557–1565.
23. Idicula, T.T., Brogger, J., Naess, H., Waje-Andreassen, U., Thomassen, L., Admission C-reactive protein after acute ischemic stroke is associated with stroke severity and mortality: the ‘Bergen stroke study’. BMC Neurol, 9, 2009, 18.
24. Muir, K.W., Weir, C.J., Alwan, W., Squire, I.B., Lees, K.R., C-reactive protein and outcome after ischemic stroke. Stroke 30 (1999), 981–985.
25. Di Napoli, M., Papa, F., Bocola, V., C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 32 (2001), 917–924.
26. Youn, C.S., Choi, S.P., Kim, S.H., et al. Serum highly selective C-reactive protein concentration is associated with the volume of ischemic tissue in acute ischemic stroke. Am J Emerg Med 30 (2012), 124–128.
27. Winbeck, K., Poppert, H., Etgen, T., Conrad, B., Sander, D., Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke 33 (2002), 2459–2464.
28. Yeh, K.H., Tsai, T.H., Chai, H.T., et al. Comparison of acute versus convalescent stage high-sensitivity C-Reactive protein level in predicting clinical outcome after acute ischemic stroke and impact of erythropoietin. J Transl Med, 10, 2012, 6.
29. Schafer, A., Fraccarollo, D., Eigenthaler, M., et al. Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability. Arterioscler Thromb Vasc Biol 25 (2005), 1071–1077.
30. Steinhubl, S.R., Badimon, J.J., Bhatt, D.L., Herbert, J.M., Luscher, T.F., Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med 12 (2007), 113–122.
31. Vaughan, C.J., Delanty, N., Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 30 (1999), 1969–1973.
32. Li, J.J., Li, Y.S., Chen, J., Yang, J.Q., Rebound phenomenon of inflammatory response may be a major mechanism responsible for increased cardiovascular events after abrupt cessation of statin therapy. Med Hypotheses 66 (2006), 1199–1204.